我们可以减缓功能下降的速度吗?
1U.O.C. of Cardiology, Casilino Polyclinic, Rome, Italy.
概括
慢性病 (CKD) 是一个全球性的健康问题. 新的心脏脏代谢药物,如SGLT2抑制剂和GLP-1受体激动剂,在减缓CKD进展和减少心血管事件方面表现有前途.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 慢性病 (CKD) 是一个主要的全球公共卫生问题,其特点是逐渐降低膜过率和增加心血管风险.
- 早期检测和病因诊断对于有效的CKD管理至关重要,因为这种疾病在早期通常是无症状的.
- 传统的CKD管理,包括血糖控制,血压优化和氨酸- ангиотензин-阿尔多斯特系统阻塞,在阻止疾病进展方面表现出有限的有效性.
研究的目的:
- 评估新型治疗剂在减缓慢性病进展方面的疗效.
- 评估这些新药对CKD患者心血管结果的影响.
- 为了突出一类新的"心脏-脏-代谢"药物的出现.
主要方法:
- 审查最近的临床研究,调查SGLT2抑制剂和GLP-1受体激动剂在CKD患者的使用.
- 对这些新药治疗患者的功能下降和心血管事件率的数据分析.
- 2型糖尿病患者和没有2型糖尿病患者之间的结局的比较.
主要成果:
- SGLT2抑制剂和GLP-1受体激动剂在减缓CKD进展方面表现出显著的有效性,无论是在患有或没有2型糖尿病的患者中.
- 这些药物还对心血管预后产生了显著的积极影响,减少了主要的心血管不良事件.
- 这些药物的有效性导致它们被归类为"心脏脏代谢"药物,扩大了它们的治疗作用,超出了糖尿病管理范围.
结论:
- 新型药物,包括SGLT2抑制剂和GLP-1受体激动剂,代表了CKD管理的重大进展.
- 这些药物提供了脏保护和心血管风险降低的双重好处.
- "心脏-脏-代谢"治疗的概念正在成为管理复杂心脏代谢和脏疾病患者的关键范式.
相关概念视频
01:17Factors Affecting Renal Clearance: Renal Impairment
48
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
48
01:11Renal Failure: Dose Adjustments
56
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
56
01:27Dialysis
252
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
252
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:22Heart Failure Drugs: Diuretics
334
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
334
01:25Antihypertensive Drugs: Direct Renin Inhibitors
469
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
469